| 张和平,张 栋,徐恩赐.ERCC1、XRCC1单核苷酸多态性与鼻咽癌放化疗敏感性的相关性研究[J].肿瘤学杂志,2017,23(1):40-44. |
| ERCC1、XRCC1单核苷酸多态性与鼻咽癌放化疗敏感性的相关性研究 |
| Relationship Between Single Nucleotide Polymorphisms of ERCC1，XRCC1 and Efficacy of Radiochemotherapy in Patients with Nasopharyngeal Cancer |
| 投稿时间：2016-07-27 |
| DOI：10.11735/j.issn.1671-170X.2017.01.B008 |
|
 |
| 中文关键词: 基因多态性 同步放化疗 敏感性 ERCC1 XRCC1 鼻咽肿瘤 |
| 英文关键词:gene polymorphism concurrent radiochemotherapy sensitivity ERCC1 XRCC1 nasopharyngeal neoplasms |
| 基金项目:常州市卫生局重大项目（ZD201114） |
|
| 摘要点击次数: 1780 |
| 全文下载次数: 572 |
| 中文摘要: |
| 摘 要：［目的］ 初步探讨ERCC1、XRCC1单核苷酸多态性与鼻咽癌患者放疗敏感性的关系。［方法］ 经病理确诊且未经放疗、化疗或手术治疗的无远处转移鼻咽癌患者100例，接受顺铂单药同步放化疗，采用TaqMan 探针实时荧光定量聚合酶链反应（polymerase chain reaction，PCR）法和直接测序法对患者外周血ERCC1、XRCC1进行多态性分析，患者同步放化疗结束后及治疗后3个月复查鼻咽部磁共振成像(MRI)测量肿瘤大小，进而分析ERCC1、XRCC1基因型与鼻咽癌同步放化疗近期治疗敏感性及远期生存率的关系。［结果］ ERCC1、XRCC1基因多态性与鼻咽癌放化疗的短期疗效无关(均P>0.05)，携带ERCC1C/C、C/T+T/T基因型患者放化疗后1年、2年、3年生存率分别为97.7%、94.3%、86.3%和98.2%、87.4%、73.8%，两组间比较差异有统计学意义（P<0.05)；携带XRCC1G/G、A/A+G/A基因型患者放化疗后1年、2年、3年生存率分别为97.7%、91%、86.4%和86.9%、82.3%、69.6%，两组间比较差异有统计学意义（P<0.05)。［结论］ ERCC1、XRCC1基因多态性与鼻咽癌同步放化疗的短期疗效无相关性，但与生存期有相关性，因此可以作为鼻咽癌放化疗生存期的预测指标。 |
| 英文摘要: |
| Abstract：［Objective］ To investigate the relationship between single nucleotide polymorphisms(SNP) of ERCC1，XRCC1 genes and efficacy of radiochemotherapy in patients with nasopharyngeal cancer(NPC). ［Methods］ One hundred patients with pathologically proved NPC received first-line cispatin-based concurrent radiochemotherapy. SNPs in ERCC1 and XRCC1 were assessed with 5’ nuclease allelic discrimination assay(TaqMan) by real-time polymerase chain reaction(RT-PCR) and direct sequencing. The size of tumor was measured by magnetic resonance imaging(MRI) after treatment completion and 3 years after treatment．The relationship between genotypes of ERCC1，XRCC1 and short-term response and overall survival was analyzed．［Results］ The short-term response of chemo-radiotherapy showed no significant correlation with the polymorphisms of ERCC1(118) and XRCC1(399) genes(P>0.05). The 1-，2-，3-year overall survival rates after radiochemotherapy in patients with genotypes of C/C and C/T+T/T of ERCC1 were 97.7%，94.3%，86.3%，and 98.2%，87.4%，73.8%，respectively(P<0.05). The 1-，2-，3-year overall survival rates after radiochemotherapy in patients with genotypes of G/G and A/A+G/A of XRCC1（399) were 97.7%，94.3%，86.3% and 98.2%，87.4%，73.8%，respectively(P<0.05). ［Conclusion］ Polymorphisms of ERCC1 and XRCC1 in NPC have no correlation with the short-term response of radiochemotherapy，but have significant correlation with overall survival of patients. Polymorphisms of ERCC1 and XRCC1 may be used as predictors of survival for NPC patients receiving radiochemotherapy． |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |